| 产品名称： | Vaccinia virus |
|---|---|
| 商品货号： | TS175512 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus |
| Strain： | Modified vaccinia virus Ankara (MVA) |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | -70°C or colder |
| Comments： | Does not replicate in human cells or the majority of mammalian cells. This is a highly attenuated strain that some experts feel can be handled safely by trained personnel without the need for vaccination. |
| Effect on Host： | CPE, rounding and sloughing |
| Recommended Host： | BHK-21 (ATCC® CCL-10™) |
| Growth Conditions： | Incubation: 37°C Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 37°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium. Incubation: 3-7 days |
| Name of Depositor： | B Moss, LS Wyatt, National Institute of Allergy and Infectious Diseases |
| Special Collection： | NCRR Contract |
| Chain of Custody： | ATCC |
| Source： | CVA (Ankara) strain serially passaged in chicken embryo fibroblasts and plaque purified three times |
| References： | Antoine G, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396, 1998. PubMed: 9601507 Bernard Moss, personal communication Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berlin Munch. Tierarztl. Wochenschr. 107: 253-256, 1994. Meyer H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038, 1991. PubMed: 2033387 Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89: 10847-10851, 1992. PubMed: 1438287 |
| Cross References： | Nucleotide (GenBank) : U94848 Vaccinia virus strain Ankara, complete genomic sequence |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Vaccinia virus |
|---|---|
| 商品货号： | TS175512 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus |
| Strain： | Modified vaccinia virus Ankara (MVA) |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | frozen 1 mL per vial |
| Storage Conditions： | -70°C or colder |
| Comments： | Does not replicate in human cells or the majority of mammalian cells. This is a highly attenuated strain that some experts feel can be handled safely by trained personnel without the need for vaccination. |
| Effect on Host： | CPE, rounding and sloughing |
| Recommended Host： | BHK-21 (ATCC® CCL-10™) |
| Growth Conditions： | Incubation: 37°C Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1-2 hours at 37°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium. Incubation: 3-7 days |
| Name of Depositor： | B Moss, LS Wyatt, National Institute of Allergy and Infectious Diseases |
| Special Collection： | NCRR Contract |
| Chain of Custody： | ATCC |
| Source： | CVA (Ankara) strain serially passaged in chicken embryo fibroblasts and plaque purified three times |
| References： | Antoine G, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396, 1998. PubMed: 9601507 Bernard Moss, personal communication Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berlin Munch. Tierarztl. Wochenschr. 107: 253-256, 1994. Meyer H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038, 1991. PubMed: 2033387 Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89: 10847-10851, 1992. PubMed: 1438287 |
| Cross References： | Nucleotide (GenBank) : U94848 Vaccinia virus strain Ankara, complete genomic sequence |
